|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||131.50 - 131.66|
|52 Week Range||105.26 - 143.90|
|Beta (5Y Monthly)||0.12|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||2.84 (2.23%)|
|Ex-Dividend Date||Aug 11, 2022|
|1y Target Est||N/A|
Immunovant (IMVT) remains focused on developing its lead pipeline candidate, batoclimab for treating several types of autoimmune diseases. The lack of other pipeline candidates remains a concern.
AstraZeneca said on Monday its cancer drug, Enhertu, developed with Japan's Daiichi Sankyo delayed the progression of a form of advanced breast cancer in previously treated patients, boosting prospects of more regulatory approvals. Enhertu met the main goal of a late-stage study testing the drug against a treatment pre-determined by physicians in people with HER2-positive metastatic breast cancer, the company said. The HER2 protein contributes to the growth and spread of breast cancer.
WILMINGTON, Del., August 12, 2022--AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by a Food and Drug Administration (FDA)-approved test, and who have received a prior systemic therapy.